UltraShape Inc.

UltraShape Inc. specializes in non-invasive body contouring solutions, utilizing advanced ultrasound technology to effectively target and reduce unwanted fat, thereby enhancing aesthetic appeal without surgical procedures. UltraShape Inc. is focused on providing innovative body contouring solutions through non-invasive methods.

The company was acquired by Syneron Medical Ltd. in February 2012 for USD 12 mn. Based in San Ramon, US, this acquisition marked a strategic pivot in their operational focus. The company was founded by individuals whose details are not publicly available.

Ultrashape specializes in non-invasive body contouring solutions, primarily aiming to reduce unwanted fat in targeted areas of the body. Their flagship product utilizes ultrasound technology to selectively disrupt fat cells while leaving surrounding tissues unharmed, providing a safe and effective method for body sculpting. This technology is designed for use in aesthetic practices, targeting end users who seek aesthetic enhancements without surgical intervention. The company serves a diverse clientele that includes medical practitioners, dermatologists, and cosmetic surgeons across major markets such as North America, Europe, and parts of Asia.

By offering advanced solutions, Ultrashape addresses the growing demand for non-surgical fat reduction methods, catering to health-conscious consumers and those seeking to improve their physical appearance. Ultrashape generates its revenue through direct sales to healthcare providers and aesthetic clinics, facilitating partnerships that enable clients to offer their body contouring solutions to end users. The transaction structure typically involves the sale of their ultrasound technology devices along with ongoing service agreements for maintenance and training. Some clients may also participate in subscription models for access to product updates and additional training resources.

Specific pricing plans for their devices and services are structured to accommodate different practice sizes, ensuring accessibility for a range of clientele. This revenue model positions Ultrashape to effectively penetrate the competitive aesthetic market while fostering long-term relationships with practitioners who deliver their innovative solutions to consumers. As part of their growth strategy, Ultrashape plans to introduce new products designed to enhance their non-invasive body contouring technologies, although specific release dates have not been provided. The company aims to expand its reach into additional markets across Europe and Asia within the next few years.

The acquisition by Syneron Medical Ltd. will support these initiatives, utilizing the USD 12 mn funding to further develop product offerings and market penetration strategies.